Relmada Therapeutics to Present at Jefferies London Healthcare Conference
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology company focusing on central nervous system diseases, has announced its participation in the Jefferies London Healthcare Conference. CEO Sergio Traversa will present on Wednesday, November 20, 2024, at 12:00 PM GMT. The presentation will be available via webcast, with a replay accessible on Relmada's website investor page for 90 days after the conference.
Relmada Therapeutics (Nasdaq: RLMD), un'azienda biotecnologica in fase avanzata focalizzata sulle malattie del sistema nervoso centrale, ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference. Il CEO Sergio Traversa presenterà mercoledì 20 novembre 2024, alle 12:00 GMT. La presentazione sarà disponibile tramite webcast, con una registrazione accessibile nella pagina investitori del sito web di Relmada per 90 giorni dopo la conferenza.
Relmada Therapeutics (Nasdaq: RLMD), una empresa de biotecnología en etapa avanzada enfocada en enfermedades del sistema nervioso central, ha anunciado su participación en la Jefferies London Healthcare Conference. El CEO Sergio Traversa presentará el miércoles 20 de noviembre de 2024, a las 12:00 PM GMT. La presentación estará disponible a través de una transmisión en vivo y se podrá acceder a una repetición en la página de inversores del sitio web de Relmada durante 90 días después de la conferencia.
Relmada Therapeutics (Nasdaq: RLMD)는 중추 신경계 질환에 주력하는 후기 단계의 생명공학 회사로, Jefferies London Healthcare Conference에 참여한다고 발표했습니다. CEO Sergio Traversa는 2024년 11월 20일 수요일 GMT 기준 오후 12시에 발표할 예정입니다. 발표는 웹캐스트로 제공되며, 회의 이후 90일 동안 Relmada의 투자자 페이지에서 재생할 수 있습니다.
Relmada Therapeutics (Nasdaq: RLMD), une entreprise de biotechnologie en phase avancée axée sur les maladies du système nerveux central, a annoncé sa participation à la Jefferies London Healthcare Conference. Le PDG Sergio Traversa présentera le mercredi 20 novembre 2024, à 12 h 00 GMT. La présentation sera disponible par webdiffusion, et un enregistrement sera accessible sur la page des investisseurs du site internet de Relmada pendant 90 jours après la conférence.
Relmada Therapeutics (Nasdaq: RLMD), ein spätstadium Biotechnologieunternehmen, das sich auf Erkrankungen des zentralen Nervensystems konzentriert, hat seine Teilnahme an der Jefferies London Healthcare Conference bekannt gegeben. CEO Sergio Traversa wird am Mittwoch, den 20. November 2024, um 12:00 Uhr GMT präsentieren. Die Präsentation wird über einen Webcast verfügbar sein, mit einer Wiedergabe, die auf der Investorenseite von Relmada für 90 Tage nach der Konferenz zugänglich ist.
- None.
- None.
Conference being held November 19-21, 2024
CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024.
Jefferies London Healthcare Conference details:
| Presentation: | Wednesday, November 20, 2024 at 12:00 PM GMT |
| Speaker: | Sergio Traversa, CEO |
| Registration: | Webcast link |
The replay of the webcast will be available on the “For Investors/Events” page of the Relmada website for 90 days following the conference.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. The Company is also developing REL-P11, a proprietary low-dose psilocybin, as an investigational agent for metabolic disease. Learn more at www.relmada.com.
Investor Contact:
Tim McCarthy
LifeSci Advisors
Tim@LifeSciAdvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When is Relmada Therapeutics (RLMD) presenting at the Jefferies London Healthcare Conference 2024?
How long will the Relmada Therapeutics (RLMD) Jefferies conference presentation replay be available?
What type of company is Relmada Therapeutics (RLMD) according to the announcement?
Where can investors access the replay of Relmada's (RLMD) Jefferies conference presentation?
